Kamao, H.; Goto, K.; Mizukawa, K.; Hiraki, R.; Miki, A.; Kimura, S.
Impact of Punctate Hyperfluorescence Status on Treatment Outcomes of Faricimab Versus Aflibercept in Neovascular Age-Related Macular Degeneration. J. Clin. Med. 2025, 14, 6637.
https://doi.org/10.3390/jcm14186637
AMA Style
Kamao H, Goto K, Mizukawa K, Hiraki R, Miki A, Kimura S.
Impact of Punctate Hyperfluorescence Status on Treatment Outcomes of Faricimab Versus Aflibercept in Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine. 2025; 14(18):6637.
https://doi.org/10.3390/jcm14186637
Chicago/Turabian Style
Kamao, Hiroyuki, Katsutoshi Goto, Kenichi Mizukawa, Ryutaro Hiraki, Atsushi Miki, and Shuhei Kimura.
2025. "Impact of Punctate Hyperfluorescence Status on Treatment Outcomes of Faricimab Versus Aflibercept in Neovascular Age-Related Macular Degeneration" Journal of Clinical Medicine 14, no. 18: 6637.
https://doi.org/10.3390/jcm14186637
APA Style
Kamao, H., Goto, K., Mizukawa, K., Hiraki, R., Miki, A., & Kimura, S.
(2025). Impact of Punctate Hyperfluorescence Status on Treatment Outcomes of Faricimab Versus Aflibercept in Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 14(18), 6637.
https://doi.org/10.3390/jcm14186637
